Documente Academic
Documente Profesional
Documente Cultură
com | Medicine
Inherited Coagulation Dis order
Management
Factor VIII Concentrate IV Infusions
Treatment Prophylaxis
Bleeding Factor VIII Level Severe Haemophilic patient
Minor 20-30 IU/dL (start prophylactic freeze-dried
st
Severe ≥ 50 IU/dL Factor VIII 3 times/week after 1
Major spontaneous joint bleed during early
Preoperative ≈ 100 IU/dL childhood)
After Surgery > 50 IU/dL
(maintain until Prevent recurrent bleeding into joints,
healing occurred) joint damage
Administration – Twice Daily
Benefits
(Half-Life – 12 hours)
Other use – Continuous infusion to cover ↓ Risk of Chronic Joints Damage
Factor VIII Gene ↓ Need for inpatient care
Location surgery
Near tip of Long arm of X Chromos ome (X q2.6 region) Complications
Extremely large gene (with 26 exons) Viral Transmission (eg. HIV, Hepatitis B, Hepatitis C)
Components of Factor VIII Protein Prevention
Triplicated region A 1A 2A 3 Exclude ↑ Risk Blood d onors,
Duplicated Homology C1C2 Test blood for HBsAg, HCV, HIV Antibodies,
Heavy glycosylated B domain (removed when Factor VIII activated) Inactivate viruses during plasma-derived concentrate preparations,
Hepatitis A and B vaccination
Causes of Haemophilia A Antibodies to Infused Factor VIII (Inhibitors)
Factor VIII Deficiency Funtionally Abnormal Prevalence – 5-10%
(90%) Protein Synthesis (10%) Mainly in severe patients
+ve Family History Spontaneous M utations Develops rarely in moderate, mild haemophilia patients
(70%) (30%) Disappear spontaneously or with continued treatment
Deletions Management
Duplications ↑ Dose Factor VIII
Frameshift mutations Recombinant Activated Factor VII
Insertions Activated Prothrombin Complex Conce ntrates
Inversions (50%) Immunosuppression with Cyclophosphamide
Intravenous Immunoglobulin
Flip-Tip Inversion Synthetic Vasopression (DDVAP)
During spermatogenesis, Single pair X chromosome pair with Y Chromosome Patients with baseline Factor VIII level > 10 IU/dL (mild haemophilia)
↓ Advantage – Avoid blood products transfusions complications
Clinical Uses
X Chromosome is longer (compared to Y chromosome)
↓
Homologous Re combination between A genes (F8A, A2, A3)
↓
Disrupted Factor VIII Gene
↓
Failure of Complete, Normal Factor VIII Protein Transcription
↓
Dysfunctional Factor VIII Protein
Antidiuretic action – lead to Hyponatremia
Laboratory Studies Other Laboratory Test Avoided in elderly
Activated Partial Thromboplastin Time (aPTT) Liver Function Test Fluid restitution after use
Prothrombin Time (PT) Renal Function Test
Platelet count Colonoscopy, Endoscopy Haemophilia A Prevention
Bleeding Time (GI Bleeding) Carrier Detection Antenatal Diagnosis
Complete Blood Count (FBC) Alpha-Fetoprotein Family History Chorionic Villous Biopsy
Specific Coagulation Factor Assay Tumour Markers Coagulation Factor Assays (8-12 weeks gestation)
vWF Measurement (↓/ Normal Factor VIII due to lyonization) Fetal Tissue for Molecular Analysis
Molecular genetic testing for Direct Fetal Blood (16-20 weeks gestation)
Factor VIII gene mutations detection obtained from umbilical vein through
Ultrasound-guided needle aspiration
↓ Factor VIII level in Fetal Blood
jslum.com | Medicine
Definition
Factor IX Deficiency
Factor IX Gene
Located close to Factor VIII gene
Factor IX Protein synthesis is Vitamin K-Dependent
Factor IX Deficiency
Incidence
0.2/5000 of Male populations
Similar with Haemophilia A
Clinical Features
Management
Methods of Prevention
Laboratory Findings
APTT – Prolonged
Factor IX Level - ↓
PT – Normal
Bleeding Time – Normal
vWF Level - Normal
Replacement Therapy
High-purity Factor IX Concentrates
↓ Frequent Infusions (d ue to ↑ Half-Life – 40-70 hours)
History
Bleeding after surgery
Prolonged Bleeding after injury
Menorrhagia (women), Abnormal bleeding after childbirth
Paradoxical Finding
Severe Deficiency – No Bleeding Tendency
Mild Deficiency – Bleed Excessively
Unusual Prese ntation
Massive Hemothorax
Cerebral Hemorrhage
Subarachnoid Hemorrhage
Spinal Epidural Hematoma with Brown-Sequard syndrome
Rare
Hematuria
Spontaneous Hemarthrosis
jslum.com | Medicine
Von Willebrand Disease
Definition Investigations
↓ Level or Abnormal Function of vWF Bleeding Time (BT) - ↑
Resulting from APTT – Normal/ ↑
Point Mutation vWF Level - ↓
Major Deletion Factor VIII Level - ↓ (frequently)
(if ↓, perform Factor VIII vWF Bindnig Assay)
Epidemiology Collagen-Binding Function - ↓
Most common in herited bleeding disorder
≈ 1 in general population (screening studies) Treatment
Women ↑ Local Measures, Antifibrinolytic agent
↑ Severe in people with Blood group type O Tranexamic acid (for mild bleeding)
Stimate/ Desmopressin Acetate (DDAVP)
Function of vWF Nasal spray (mild von Willebrand disease)
Link between Subendothelial ECM, Platelet glycoprotein Induce release of vWF stored in Weibel-Palade bodies (in Endothelial cells)
Carrier molecule for Factor VIII ↑ Plasma levels of vWF
Stored in Endothelial cells, Platelet Carry no risk of Infectious disease (synthetic product)
Factor VIII Concentrate Infusion (rich in von Wille brand Factor)
For Excessive Bleeding
Humate-P
Alphanate (Antihemophilic factor)
↓ Bleeding in patients undergoing surgery, invasive procedure
Contraindications
Aspirin, Pain Killer
Interfere Platelet function, cause bleeding
Clinical
Mucous Membrane Bleeding (eg. Epistaxis, Menorrhagia)
Excessive Blood Loss
Superficial cuts
Abrasion
Operative
Post-traumatic haemorrhage
Haemarthroses, Muscle Haematomas (Rare - Except in Type 3 Disease)
Bleeding
Intermittent
Provoked by Aspirin use
jslum.com | Medicine
SD – Solvent/ Detergent
jslum.com | Medicine
Physiotherapy Management of Haemophilia
Recreational Activities
Recommended Discouraged
Swimming Football
Cycling Boxing
Walking Skating
Darts Volleyball
Ping pong Jumping
Bowling Basketball
Snooker Skiing
Golf
Tennis
Jogging
Weight lifting
Gymnastics